Patents Assigned to Arbutus Biopharma Corporation
-
Publication number: 20220023427Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: ApplicationFiled: June 24, 2021Publication date: January 27, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20220000778Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Lorne Ralph PALMER, Petra SCHREINER
-
Publication number: 20220001029Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (b) a cationic lipid of formula CL1 or CL2, and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Kieu Mong LAM, Alan D. MARTIN, Petra SCHREINER
-
Patent number: 11191849Abstract: The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.Type: GrantFiled: June 30, 2017Date of Patent: December 7, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Michael J. Abrams, James Heyes, Adam Judge, Kieu Mong Lam, Lorne Ralph Palmer, Stephen P. Reid, Edward D. Yaworski
-
Patent number: 11141378Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: April 12, 2021Date of Patent: October 12, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Patent number: 11130740Abstract: The present invention includes substituted 2,3-dihydro-1H-indene analogs, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.Type: GrantFiled: April 24, 2018Date of Patent: September 28, 2021Assignee: Arbutus Biopharma CorporationInventors: Yingzhi Bi, Bruce D. Dorsey, Christopher Brooks Moore
-
Publication number: 20210284733Abstract: Certain embodiments of the invention provide a method for treating a Hepatitis B virus infection and/or ameliorating one or more symptoms associated with a Hepatitis B virus infection in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an anti-PD-1 antibody, or fragment thereof.Type: ApplicationFiled: August 21, 2017Publication date: September 16, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Christopher Brooks MOORE, Jang-June PARK
-
Publication number: 20210275455Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210275454Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210267895Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: April 12, 2021Publication date: September 2, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20210267891Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: March 16, 2021Publication date: September 2, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Patent number: 11098010Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.Type: GrantFiled: March 20, 2018Date of Patent: August 24, 2021Assignee: Arbutus Biopharma CorporationInventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
-
Patent number: 11077197Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure XXXIII, wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: June 8, 2017Date of Patent: August 3, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Publication number: 20210220274Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: November 10, 2020Publication date: July 22, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20210207140Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: March 16, 2021Publication date: July 8, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20210162053Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.Type: ApplicationFiled: October 7, 2020Publication date: June 3, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
-
Patent number: 11013726Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.Type: GrantFiled: March 30, 2020Date of Patent: May 25, 2021Assignee: Arbutus Biopharma CorporationInventors: Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
-
Patent number: 11001564Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.Type: GrantFiled: September 13, 2017Date of Patent: May 11, 2021Assignee: Arbutus Biopharma CorporationInventors: Andrew G. Cole, Steven Kultgen
-
Patent number: 10953095Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).Type: GrantFiled: October 4, 2019Date of Patent: March 23, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
-
Publication number: 20210047640Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target ApoC3 and ANGPTL3 expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating hypertriglyceridemia in humans).Type: ApplicationFiled: April 16, 2020Publication date: February 18, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ting CHIU, Narayanan HARIHARAN, Amy C. H. LEE, Christopher Justin PASETKA, Janet Ruth PHELPS, Nicholas Michael SNEAD, Andrew Anthony WIECZOREK